SEC Form 4 · accession 0001571211-16-000002
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay R. Luly
Officer — President and CEO · Director
Period of report
Jul 20, 2016
Accepted (ET)
Jul 22, 2016 · 4:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.00 | Jul 20, 2016 | A | 6,967 | A | Jul 20, 2016 | Mar 20, 2023 | Common Stock | 6,967 | 6,967 | D |
Explanation of responses
- F1On March 20, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which does not become reportable on Form 4 until the option becomes exercisable. The option becomes exercisable in up to nine installments, six of which are installments of 8.33% of the shares and three of which are installments of 16.67% of the shares, based on ENTA's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. Two other installments of the option shares have previously become exercisable.